Momenta Pharmaceuticals Receives Orphan Drug Designation for Necuparanib (Formerly M402) in Pancreatic Cancer
05 juin 2014 08h01 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., June 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that its novel oncology candidate, necuparanib (formerly M402), has received Orphan Drug...
Momenta Pharmaceuticals Reports First Quarter 2014 Financial Results
06 mai 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 6, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2014.
For the first quarter...
Momenta Pharmaceuticals Announces Presentation of Data Supporting Sialylation Platform
02 mai 2014 08h47 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 2, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
30 avr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
15 avr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 15, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals to Webcast Presentation at the Cowen and Company 34th Annual Health Care Conference
24 févr. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 24, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial Results
10 févr. 2014 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 10, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the fourth quarter and year ended December 31, 2013.
For the...
Momenta Pharmaceuticals to Webcast Presentation at the 2014 Leerink Global Healthcare Conference
05 févr. 2014 08h30 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Feb. 5, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End 2013 Financial Results Conference Call and Webcast
21 janv. 2014 16h05 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Jan. 21, 2014 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Appoints Michael Franken, M.D. as President, Biosimilars Business
12 déc. 2013 08h00 HE
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) announced today that it has named Michael Franken, M.D. as President, Biosimilars Business. Dr. Franken...